Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Acer Therapeutics Inc (NASDAQ:ACER)

17.43
Delayed Data
As of Nov 22
 0.00 / 0.00%
Today’s Change
5.70
Today|||52-Week Range
22.63
+82.94%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$112.4M

Company Description

Acer Therapeutics, Inc. is pharmaceutical company, which engages in th acquisition, development, and intends to commercialize therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Its products include Edsivo and ACER-001. Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling and is headquartered in Cambridge, MA.

Contact Information

Acer Therapeutics, Inc.
222 Third Street
Cambridge Massachusetts 02142
P:(844) 902-6100
Investor Relations:

Employees

Shareholders

Individual stakeholders29.33%
Mutual fund holders0.21%
Other institutional-0.18%

Top Executives

Christopher SchellingPresident, Chief Executive Officer & Director
Harry S. PalminChief Financial Officer
William T. AndrewsChief Medical Officer
Pamela M. WilliamsonVice President-Regulatory Affairs